Evidence-based prescribing of statins: a developing world perspective.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts.BMC cardiovascular disorders · 2018
   Article
2. Synthetic biology: ensuring the greatest global value.Systems and synthetic biology · 2013
   Article
3. National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool.Therapeutics and clinical risk management · 2013
   Article
4. Should risky treatments be reserved for secondary prevention? Theoretical considerations regarding risk-benefit tradeoffs.Journal of clinical epidemiology · 2012
   Article
5. Statins everyday versus alternate days: Is there a difference in myalgia rates?Indian heart journal
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as